Pharmaceutical composition for treating primary trigeminal neuralgia

A technology of trigeminal neuralgia and composition, which is applied in drug combination, drug delivery, nervous system diseases, etc., and can solve problems such as poor therapeutic effect, high risk, and large side effects of carbamazepine

Inactive Publication Date: 2017-09-08
臧运华
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are particularly sensitive trigger points in the distribution area of ​​the trigeminal nerve, and the pain is often limited to one or more branches of the unilateral trigeminal nerve. In recent years, thanks to the development of microvascular decompression in neurosurgery, the primary Trigeminal neuralgia is also closely related to facial microvascular, the main reason is that adjacent blood vessels compress the trigeminal nerve root, most of them are small glue arteries compressing the nerve root from the upper or inner upper part of the trigeminal nerve root, a few Because the anterior inferior cerebellar artery compresses the nerve root from below the root of the trigeminal nerve, as a response, the more commonly used methods in clinical practice focus on neurosurgery, peripheral branch avulsion, amputation, and trigeminal nerve tractectomy It is suitable for patients of all ages, and it is relatively painful, high-risk, and expensive; in the field of neurology, most of them can only passively control and alleviate the disease by taking carbamazepine or alcohol injection, but the treatment effect is poor , long recovery period, and easy recurrence. Carbamazepine, the first choice drug for trigeminal neuralgia, is difficult to be used for a long time due to its large side effects or high risk

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Measure scorpion, tortoise shell, cassia seed, Yuanhu, dried blood, bezoar, bear bile, Nansha ginseng, Gansong, Chuanbei, Polygonatum odoratum, Vitex, cinnamon, lark, dodder, hippocampus according to the formula The decoction pieces are crushed into powdered medicine and passed through a 50-mesh sieve, soaked in deionized water at 45°C for half an hour, filtered with gauze to obtain the medicinal residue, wrapped with the gauze and tied in the mouth, and put into In the automatic decoction machine, add 2500g of water, decoct under normal temperature and pressure for 3 hours, remove the medicine bag, and divide the obtained medicinal liquid to obtain decoction A.

Embodiment 2

[0043] (1) Monarch medicine decoction: Take the decoction pieces of scorpion, tortoise shell, and cassia seed twice as much as the formula, grind them into powder and pass through a 100-mesh sieve, soak the powder after sieving with deionized water at 45°C for 1 hour, Use double-layer non-woven fabric to filter the medicinal mud, wrap the medicinal mud with the double-layer non-woven fabric and tie the mouth, put it into an automatic decoction machine, add 200g of water, and decoct at a working pressure of 170kPa and a temperature of 130°C for 1 hour, remove the non-woven medicine bag, add 10g honey to the medicinal liquid, continue to decoct for 2 hours under normal temperature and differential pressure, until the medicinal liquid is concentrated into a paste, and the monarch drug ointment is obtained;

[0044] (2) Decoction of ministerial medicine: take the decoction pieces of Yuanhu, blood dried fruit, bezoar, and bear bile in the prescribed amount, crush them into powdered ...

Embodiment 3

[0049] (1) Pretreatment of raw materials: take three times the amount of the formula of scorpion, tortoise shell and cassia; Polygonatum odoratum, Vitex, cinnamon, lark, dodder, hippocampus, pulverized and mixed, added 1200g deionized water, decocted at normal temperature and pressure for 6 hours, filtered once to obtain a medicinal solution, and added 800g deionized to the filter residue Water, decocted at a pressure of 80kPa and a temperature of 120°C for 4 hours, filtered to obtain a second medicinal solution, then added 400g of deionized water to the residue, decocted at a pressure of 170kPa and a temperature of 130°C for 2 hours, filtered to obtain a third medicinal solution liquid; above-mentioned one, two, three medicinal liquids are combined, add 300g honey in the merged medicinal liquid, continue decocting 3 hours under the normal temperature differential pressure, until the medicinal liquid is concentrated into paste shape, obtain the pretreatment raw material medicin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition for treating primary trigeminal neuralgia. The pharmaceutical composition is prepared from the following raw medicinal materials: scorpio, tortoise shell, semen cassia, rhizoma corydalis, dragon's blood, calculus bovis, fel ursi, adenophora tetraphylla, rhizoma nardostachyos, tendril-leaved fritillary bulb, radix polygonati officinalis, fructus viticis, cinnamon, marsdenia longipes, semen cuscutae and sea horse, wherein the scorpio, tortoise shell and semen cassia are taken as the monarch drug; the rhizoma corydalis, dragon's blood, calculus bovis and fel ursi are taken as the ministerial drug; the adenophora tetraphylla, rhizoma nardostachyos, tendril-leaved fritillary bulb, radix polygonati officinalis are taken as the adjuvant; and the fructus viticis, cinnamon, marsdenia longipes, semen cuscutae and sea horse are taken as the conductant drug. The pharmaceutical composition prescription for treating primary trigeminal neuralgia, disclosed by the invention, is simple in drug flavor, and the various flavors of medicines achieve respective effects, are coordinated with one another, and are compounded together to achieve unexpected technical effects in the aspect of treating the primary trigeminal neuralgia. At present, more than 300 patients of various kinds are cured, and the effective rate can reach 97% or higher. The pharmaceutical composition disclosed by the invention has the advantages of fast efficacy, high efficiency, short course of treatment, difficulty in reoccurrence and the like. In addition, the special four-quadrant preparation process is easy to master and apply.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicine, relates to a neurology medicine, in particular to a medicine composition for treating primary trigeminal neuralgia. Background technique [0002] Trigeminal neuralgia is a common disease in neurology. It is characterized by recurrent paroxysmal severe pain in the trigeminal nerve distribution area on one side of the face. The symptoms are characterized by sudden onset and sudden arrest in the trigeminal nerve distribution area of ​​the head and face. , Lightning-like, knife-like, burning-like, intractable, unbearable severe pain, which affects normal life and work. According to domestic statistics, the incidence rate of this disease is about 52 cases per 100,000 people. Among them, primary trigeminal neuralgia is the most common type of trigeminal neuralgia. Primary trigeminal neuralgia usually stops suddenly after a few seconds to a few minutes without other complications. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/8969A61K9/08A61K9/00A61P25/02A61K35/413A61K35/586A61K35/60A61K35/646
CPCA61K9/0095A61K9/08A61K35/413A61K35/586A61K35/60A61K35/646A61K36/27A61K36/342A61K36/39A61K36/43A61K36/482A61K36/54A61K36/66A61K36/84A61K36/85A61K36/889A61K36/896A61K36/8966A61K36/8969A61K2236/331A61K2236/39A61K2236/53A61K2300/00
Inventor 臧运华高向慧郑志轩王群周喜燕
Owner 臧运华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap